



---

***Condensed Interim  
Unconsolidated Financial  
Information for the  
Nine Months Period  
Ended 31 March 2017***

---



**FEROZSONS**  
LABORATORIES LIMITED

## **CONTENTS**

---

Corporate Information	3
Directors' Review Report	4
Condensed Interim Balance Sheet	8
Condensed Interim Profit and Loss Account	10
Condensed Interim Statement of Comprehensive Income	11
Condensed Interim Statement of Changes in Equity	12
Condensed Interim Cash Flow Statement	13
Notes to the Condensed Interim Financial Information	14
Consolidated Accounts	
Condensed Interim Consolidated Balance Sheet	24
Condensed Interim Consolidated Profit and Loss Account	26
Condensed Interim Consolidated Statement of Comprehensive Income	27
Condensed Interim Consolidated Statement of Changes in Equity	28
Condensed Interim Consolidated Cash Flow Statement	29
Notes to the Condensed Interim Consolidated Financial Information	30

## CORPORATE INFORMATION

### Board of Directors

Mrs. Akhter Khalid Waheed	Chairperson	Non-Executive Director
Mr. Osman Khalid Waheed	Chief Executive Officer	Executive Director
Mrs. Amna Piracha Khan		Non-Executive Director
Ms. Munize Azhar Peracha		Non-Executive Director
Mr. Farooq Mazhar		Non-Executive Director
Mr. Nihal F Cassim		Non-Executive Director
Mr. Shahid Anwar		Independent Director

### Audit Committee

Mr. Shahid Anwar	Chairman
Mrs. Amna Piracha Khan	Member
Mr. Farooq Mazhar	Member
Mr. Nihal F Cassim	Member

### Investment Committee

Mr. Farooq Mazhar	Chairman
Mr. Osman Khalid Waheed	Member
Mr. Nihal F Cassim	Member

### HR & Remuneration Committee

Mr. Shahid Anwar	Chairman
Mr. Farooq Mazhar	Member
Mr. Nihal F Cassim	Member

### Company Secretary/Chief Financial Officer

Syed Ghausuddin Saif

### Share Registrar

CorpTec Associates (Pvt.) Limited  
503-E, Johar Town, Lahore, Pakistan  
Telephone: +92-42-35170336-37  
Fax: +92-42-35170338

### Head of Internal Audit

Mr. Rizwan Hameed Butt

### Factory

P.O. Ferozsons  
Amangarh  
Nowshera (KPK), Pakistan  
Telephone: +92-923-614295, 610159  
Fax: +92-923-611302

### External Auditors

KPMG Taseer Hadi & Co.  
Chartered Accountants

### Internal Auditors

EY Ford Rhodes  
Chartered Accountants

### Bankers

Habib Bank Limited  
MCB Bank Limited  
Meezan Bank Limited  
Bank Al-Habib Limited  
Bank Alfalah Limited  
Habib Metropolitan Bank Limited  
Allied Bank Limited

### Head Office

5 K.M - Sunder Raiwind Road  
Lahore, Pakistan  
Telephone: +92-42-36026700  
Fax: +92-42-36026701-2

### Legal Advisors

Khan & Piracha

### Sales Office Lahore

43-Al Noor Building  
Bank Square, The Mall  
Lahore, Pakistan  
Telephone: +92-42-37358194  
Fax: +92-42-37313680

### Registered Office

Ferozsons Laboratories Limited  
197-A, The Mall  
Rawalpindi-46000, Pakistan  
Telephone: +92-51-4252155-57  
Fax: +92-51-4252153  
Email: cs@ferozsons-labs.com

### Sales Office Karachi

House No. 9, Block 7/8,  
Maqbool Cooperative Housing Society,  
Shahrah-e-Faisal, Karachi, Pakistan  
Telephone: +92-21-34386852  
Fax: +92-21-34386754

(The quarterly accounts can be downloaded from Company's Website: [www.ferozsons-labs.com](http://www.ferozsons-labs.com))

## DIRECTORS' REVIEW REPORT ON CONDENSED INTERIM FINANCIAL INFORMATION FOR THE NINE MONTHS PERIOD ENDED 31 MARCH 2017

We are pleased to present a brief review of your Company's un-audited Standalone and Consolidated condensed interim financial information for the nine months ended 31 March 2017. The consolidated condensed interim financial information incorporates the Company's 98% owned venture Farmacia and 80% owned subsidiary BF Biosciences Limited.

### OPERATIONAL AND FINANCIAL PERFORMANCE

A summary of operating results for the period is given below:

	Individual				Consolidated			
	9 Months	9 Months	3 Months	3 Months	9 Months	9 Months	3 Months	3 Months
	31-Mar-17	31-Mar-16	31-Mar-17	31-Mar-16	31-Mar-17	31-Mar-16	31-Mar-17	31-Mar-16
	(Rupees in thousands)							
<b>Sales (net)</b>	<b>3,175,090</b>	8,471,076	<b>866,243</b>	2,608,577	<b>3,710,299</b>	9,337,846	<b>1,043,690</b>	2,869,967
<b>Gross Profit</b>	<b>1,453,267</b>	3,422,938	<b>382,269</b>	1,028,742	<b>1,587,016</b>	3,807,207	<b>419,385</b>	1,115,026
<b>Profit before tax</b>	<b>586,415</b>	2,388,371	<b>112,749</b>	659,492	<b>609,039</b>	2,582,242	<b>119,507</b>	687,606
<b>Taxation</b>	<b>(119,765)</b>	(482,295)	<b>(5,186)</b>	(163,315)	<b>(123,445)</b>	(536,676)	<b>(8,466)</b>	(167,598)
<b>Profit after tax</b>	<b>466,651</b>	1,906,076	<b>107,563</b>	496,177	<b>485,594</b>	2,045,566	<b>111,041</b>	520,008

Standalone Net Sales of your Company decreased by 63% for the nine months and 67% for the 3rd quarter in comparison to the respective corresponding period last year. At the group level, Net Sales showed a decline of 60% over the nine months and 64% for the 3rd quarter ended 31 March 2017, respectively.

The decline in Net Sales of the Company is mainly due to decrease in the sales of its imported products for HCV under franchise from Gilead Sciences Inc. Net Sales outside Gilead portfolio increased by 8% as compared to same period last year. The Quarter under review has been a difficult one for the pharmaceutical industry, which as a whole suffered a decline of 6% for the Quarter under review.

Gross Profit (GP) percentage margins have shown an improvement of 5% in both nine months and 3rd quarter, reflecting the reduction in sales mix of imported products, which carry lower GP margin. At the group level, Gross Profit margins have shown a growth of 2% in nine months and 1% in 3rd quarter respectively.

Your Company reported Net Profit after Tax (NPAT) of Rs. 107.56 million for the Quarter and Rs. 466.65 million for nine months ended 31 March 2017.

Based on the Net Profit for the nine months ended 31 March 2017, the Earnings per Share (EPS), both basic and diluted, stand at Rs. 15.46 compared to EPS of Rs. 63.14 of same period last year.

### BF Biosciences Limited Operational Status

The Company's subsidiary company BF Biosciences Limited closed its Net Sales at Rs. 456.26 million for the nine months ended 31 March 2017, with a decline of 45% in comparison with the last year same period. Net Profit after Tax (NPAT) for the nine months under review stood at Rs. 34.80 million. The decline in operating results of the subsidiary is primarily due to introduction of oral treatment regimens for HCV patients and the corresponding decline in the market for Interferon. Apart from its HCV segment, the

Oncology portfolio of BF Biosciences Limited have shown a growth of 17% as compared to corresponding period.

#### **Future Outlook**

The current year under review has been a challenging one for the Company, particularly as several unlicensed generics of its HCV franchise have flooded the market. However, management is continuously working to explore growth opportunities and have a cautiously optimistic outlook for the business going forward.

The Company has filed application with DRAP for the registration of Epclusa ®, a pan-genotypic agent for the treatment of HCV. The import of Epclusa ®, on patient basis is expected to start in next quarter of the current financial year. Epclusa, which has 50% reduced treatment duration, and demonstrates high cure rates across all genotypes of HCV, presents another opportunity to change the landscape of HCV treatment in the country.

An added difficulty for the company during the Quarter under review has been the controversy around registration of medical devices in Pakistan. As the importer and distributor of Boston Scientific's range of medical devices, the company has always taken its regulatory responsibilities seriously, and registered its medical devices with DRAP well in time. However, in the confusion and chaos resulting from the recent controversy related to unregistered devices, all device imports came to a standstill, including those that were registered, resulting in shortages in the market. In the long term, there is no doubt that quality regulation of medical devices will be to the benefit of patients as well as quality device manufacturers, the supply shocks in the short term have been a detriment to the industry and the company's growth. The Medical Device Registration Rules are currently under review, and we hope that imports of medical devices will soon be regularized.

#### **Acknowledgments**

We would like to acknowledge the considerable efforts and dedication of our employees towards achievement of the Company's Objectives.

We would also like to thank our principals and business partners for their continuous support and confidence in our Company as well as our valued customers for their continued trust in our products.

**For and on behalf of the Board of Directors**

**(Mrs. Akhter Khalid Waheed)**  
Chairperson

**31 مارچ 2017 پر ختم ہونے والی نوامی کے مختصر عبوری مالیاتی نتائج پر ڈائریکٹرز کی جائزہ رپورٹ**

ہم انتہائی مسرت سے 31 مارچ 2017 پر ختم ہونے والی نوامی کیلئے کمپنی کے فیروز پڑتال شدہ انفرادی اور انضمام کردہ مختصر عبوری مالیاتی نتائج پیش کرتے ہیں۔ انضمام کردہ مختصر عبوری مالیاتی نتائج میں فارمیٹڈ شیئر (98 فیصد ملکیت) اور ڈیلی کیٹی بیف (80 فیصد ملکیت) کے مالیاتی نتائج ضم کئے گئے ہیں۔

آپریشنل اور مالیاتی کارکردگی

زیر جائزہ مدت کے آپریشنل نتائج کا خلاصہ نیچے دیا گیا ہے:

انضمام کردہ				انفرادی			
نوامی	نوامی	نوامی	نوامی	نوامی	نوامی	نوامی	نوامی
31 مارچ 2016	31 مارچ 2017	31 مارچ 2016	31 مارچ 2017	31 مارچ 2016	31 مارچ 2017	31 مارچ 2016	31 مارچ 2017
(ہزار روپے)							
2,869,967	1,043,690	9,337,846	3,710,299	2,608,577	866,243	8,471,076	3,175,090
1,115,026	419,385	3,807,207	1,587,016	1,028,742	382,269	3,422,938	1,453,267
687,606	119,507	2,582,242	609,039	659,492	112,749	2,388,371	586,415
(167,598)	(8,466)	(536,676)	(123,445)	(163,315)	(5,186)	(482,295)	(119,765)
520,008	111,041	2,045,566	485,594	496,177	107,563	1,906,076	466,651
<b>خالص فروخت</b>							
<b>کل منافع</b>							
<b>قبل از ٹیکس منافع</b>							
<b>ٹیکس</b>							
<b>بعد از ٹیکس منافع</b>							

کمپنی کی انفرادی فروخت (خالص) میں اس نوامی کے دوران گزشتہ سال کی اسی نوامی کے مقابلے میں 63% کمی ہوئی جبکہ تیسری سہ ماہی کے دوران گزشتہ سال کی اسی سہ ماہی کے مقابلے میں 67% کمی دیکھنے میں آئی۔ گروپ کی فروخت (خالص) میں 31 مارچ 2017 پر ختم ہونے والی نوامی کے دوران گزشتہ سال کی اسی نوامی کے مقابلے میں 60% کمی دیکھنے میں آئی جبکہ 31 مارچ 2017 پر ختم ہونے والی تیسری سہ ماہی کے دوران گزشتہ سال کی اسی سہ ماہی کے مقابلے میں 64% کمی واقع ہوئی۔

کمپنی کی فروخت (خالص) میں کمی کی بڑی وجہ ان مصنوعات کی فروخت میں کمی ہے جو کمپنی گلیڈ سائنسز انکارپوریٹڈ سے فرنیچر کے تحت HCV کیلئے درآمد کرتی ہے۔ گلیڈ پورٹ فولیو کے علاوہ دیگر مصنوعات کی فروخت (خالص) میں پچھلے سال کے اسی عرصہ کے مقابلے میں 8% اضافہ ہوا۔ زیر جائزہ سہ ماہی فارماسیوٹیکل انڈسٹری کیلئے مشکل رہی ہے جس میں اس سہ ماہی کے دوران مجموعی طور پر 6% کمی دیکھنے میں آئی۔

کل منافع کی گنجائش میں اس نوامی اور تیسری سہ ماہی کے دوران 5% اضافہ ہوا، جس کی وجہ درآمد کردہ مصنوعات کی تناسب فروخت میں کمی ہے کیونکہ درآمد کردہ مصنوعات پر کل منافع کی گنجائش کم ہوئی ہے۔ گروپ کے لحاظ سے کل منافع کی گنجائش میں اس نوامی کے دوران 2% اضافہ جبکہ تیسری سہ ماہی کے دوران 1% اضافہ ہوا۔

31 مارچ 2017 پر ختم ہونے والی سہ ماہی اور نوامی کے دوران کمپنی کا بعد از ٹیکس خالص منافع (NPAT) بائرنٹیپ 107.56 ملین روپے اور 466.65 ملین روپے رہا۔

31 مارچ 2017 پر ختم ہونے والی نوامی کے خالص منافع کی بنیاد پر، بنیادی اور تھمیل کردہ فی حصص آمدن (EPS) 15.46 روپے رہی جبکہ پچھلے سال کے اسی نوامی میں بنیادی اور تھمیل کردہ فی حصص آمدن (EPS) 63.14 روپے تھی۔

BF بائیو سائنسز لمیٹڈ کی آپریشنل صورتحال

31 مارچ 2017 پر ختم ہونے والی نوامی کے دوران کمپنی کی ڈیلی کیٹی بیف بائیو سائنسز لمیٹڈ کی فروخت (خالص) 456.26 ملین روپے رہی، جس میں پچھلے سال کی اسی نوامی کے مقابلے میں 45% کمی آئی۔ زیر جائزہ نوامی کے دوران بعد از ٹیکس خالص منافع (NPAT) 34.80 ملین روپے رہا۔ ڈیلی کیٹی کے آپریشنل نتائج میں کمی کی وجہ HCV

کے مریضوں کیلئے منہ کے ذریعے لے جانے والی ادویات کی ایجاد ہے، جس سے انٹرفیرونز کی فروخت میں کمی آئی۔ HCV کے سیگنٹ کو پیچھے رکھتے ہوئے دیکھا جائے تو BF ہائیدو سائیکلیمینڈ کے کینسر سے متعلقہ (آنکولوجی) پورٹ فولیو میں پچھلے سال کے اسی عرصہ کے مقابلہ میں 17% اضافہ دیکھنے میں آیا۔

#### مشغول کے امکانات کا جائزہ

یہ زیر جائزہ سال کینی کیلئے مشکل رہا ہے، خاص طور پر اس لئے کہ مارکیٹ میں کینی کی HCV کی فریجائز کے غیر لائسنس شدہ جنیرکس کی بھرمار ہو گئی ہے۔ تاہم، انتظامیہ ترقی کے مواقع تلاش کرنے کیلئے مسلسل کام کر رہی ہے اور با احتیاط طور پر کاروبار کی ترقی کے بارے پر امید ہے۔

کینی نے ایچکوسا® (HCV کے علاج کیلئے ایک نیا - جینوٹائپ ایجنٹ) کی رجسٹریشن کیلئے DRAP کو درخواست دے رکھی ہے۔ توقع ہے کہ مریضوں کی بنیاد پر ایچکوسا® کی دوا اس مالی سال کی اگلی سہ ماہی میں شروع ہو جائے گی۔ ایچکوسا کے ذریعے ملک میں HCV کے علاج کا منظر نامہ بدلنے کا ایک اور موقع ہاتھ میں آیا ہے کیونکہ ایچکوسا سے HCV کے علاج کا دورانیہ 50% کم ہو جاتا ہے اور HCV کے تمام جینوٹائپس کیلئے بلند شرح علاج دیکھنے کو ملی ہے۔

پاکستان میں طبی آلات کی رجسٹریشن کا تنازعہ زیر جائزہ سہ ماہی کے دوران کینی کیلئے مزید مشکل کا موجب بنا۔ بوسٹن سائنٹفک کے طبی آلات کی اپورٹ اور ڈسٹری بیوٹر ہونے کے ناطے کینی نے ہمیشہ اپنی قانونی ذمہ داریوں کو سنجیدگی سے لیا ہے اور اپنے طبی آلات کو DRAP کے ساتھ بروقت رجسٹر کروایا ہے۔ تاہم غیر رجسٹرڈ آلات سے متعلق حالیہ تنازعہ میں پیدا ہونے والی بے یقینی اور افراطی کی وجہ سے تمام آلات کی درآمد روک دی گئی جس میں رجسٹرڈ آلات بھی شامل تھے، جسکی وجہ سے مارکیٹ میں قلت پیدا ہو گئی۔ اس بات میں کوئی شک نہیں کہ طویل مدت میں طبی آلات کے معیار کیلئے قوانین سے مریضوں اور معیاری آلات بنانے والی کمپنیوں کو فائدہ پہنچے گا، مگر قلیل مدت میں آلات کی فراہمی میں قحطی انڈسٹری اور کینی کی ترقی کیلئے نقصان دہ رہا۔ طبی آلات کی رجسٹریشن کے ضابطہ کار (میڈیکل ڈیوائس رجسٹریشن رولز) کا اس وقت جائزہ لیا جا رہا ہے اور ہم امید کرتے ہیں کہ طبی آلات کی درآمد کا ضابطہ کار جلد طے پا جائے گا۔

#### اعتراف

ہم کینی کے مقاصد کے حصول کیلئے اپنے ملازمین کی نمایاں کوششوں اور لگن کا اعتراف کرنا چاہتے ہیں۔

ہماری کینی پر اعتماد اور مسلسل حمایت کیلئے ہم اپنے عہدیداروں اور کاروباری شراکت داروں کا شکریہ ادا کرتے ہیں اور ہماری مصنوعات پر مسلسل بھروسہ رکھنے کیلئے ہم اپنے خریداروں کا شکریہ بھی ادا کرتے ہیں۔

یورڈ آف ڈائریکٹرز کی جانب سے

(مسز اختر خالد وجید)

چیئر پرسن

**CONDENSED INTERIM UNCONSOLIDATED BALANCE SHEET  
 AS AT 31 MARCH 2017**

	Un-Audited 31 March 2017	Audited 30 June 2016
<b>Note</b>	-----Rupees-----	
<b>EQUITY AND LIABILITIES</b>		
<b><i>Share capital and reserves</i></b>		
Authorized share capital 50,000,000 (30 June 2016: 50,000,000) ordinary shares of Rs. 10 each	<b>500,000,000</b>	500,000,000
Issued, subscribed and paid up capital	<b>301,868,410</b>	301,868,410
Capital reserve	<b>321,843</b>	321,843
Accumulated profit	<b>3,799,750,619</b>	3,765,936,024
	<b>4,101,940,872</b>	4,068,126,277
<b>Surplus on revaluation of property, plant and equipment - net of tax</b>	<b>812,830,585</b>	832,797,085
<b><i>Non current liabilities</i></b>		
Deferred taxation	<b>165,231,001</b>	149,191,075
<b><i>Current liabilities</i></b>		
Trade and other payables	<b>531,462,879</b>	651,474,148
Short term borrowings - secured	<b>231,020,721</b>	-
Accrued mark-up	<b>2,239,083</b>	32,767
	<b>764,722,683</b>	651,506,915
	<b>5,844,725,141</b>	5,701,621,352
<b>Contingencies and commitments</b>	<b>5</b>	

The annexed notes from 1 to 16 form an integral part of this condensed interim unconsolidated financial information.

\_\_\_\_\_  
 Chief Executive Officer

		<b>Un-Audited 31 March 2017</b>	<b>Audited 30 June 2016</b>
	<b>Note</b>	<b>-----Rupees-----</b>	
<b>ASSETS</b>			
<b><u>Non-current assets</u></b>			
Property, plant and equipment	6	<b>2,600,996,375</b>	2,384,990,408
Intangibles		<b>2,783,476</b>	4,174,991
Long term investments	7	<b>275,935,149</b>	263,310,134
Long term deposits		<b>7,066,325</b>	6,351,325
		<b><u>2,886,781,325</u></b>	<u>2,658,826,858</u>
<b><u>Current assets</u></b>			
Stores, spare parts and loose tools		<b>27,790,070</b>	22,249,383
Stock in trade		<b>1,724,793,030</b>	1,866,923,740
Trade debts - considered good		<b>534,021,648</b>	387,586,473
Loans and advances - considered good		<b>123,821,460</b>	35,476,550
Deposits and prepayments		<b>118,195,034</b>	92,321,784
Other receivables		<b>8,213,819</b>	7,637,820
Short term investments	8	<b>207,585,321</b>	335,000,000
Income tax - net		<b>113,637,020</b>	45,918,965
Cash and bank balances	9	<b>99,886,414</b>	249,679,779
		<b>2,957,943,816</b>	3,042,794,494
		<b><u><u>5,844,725,141</u></u></b>	<u><u>5,701,621,352</u></u>

\_\_\_\_\_  
Director

**CONDENSED INTERIM UNCONSOLIDATED  
 PROFIT AND LOSS ACCOUNT (UN-AUDITED)  
 FOR THE NINE MONTHS PERIOD ENDED 31 MARCH 2017**

	Note	Nine months period ended		Three months period ended	
		31 March 2017	31 March 2016	31 March 2017	31 March 2016
		<b>Rupees</b>			
Revenue - net	10	3,175,089,688	8,471,075,710	866,243,292	2,608,577,091
Cost of sales	11	(1,721,822,556)	(5,048,138,139)	(483,974,753)	(1,579,834,969)
<b>Gross profit</b>		<b>1,453,267,132</b>	<b>3,422,937,571</b>	<b>382,268,539</b>	<b>1,028,742,122</b>
Administrative expenses		(206,644,771)	(181,882,768)	(70,251,725)	(58,030,565)
Selling and distribution expenses		(637,892,515)	(701,737,564)	(206,777,682)	(254,850,641)
Other expenses		(46,233,066)	(238,807,153)	(4,620,953)	(89,980,054)
Other income		37,469,248	96,049,063	15,336,432	35,993,068
<b>Profit from operations</b>		<b>599,966,028</b>	<b>2,396,559,149</b>	<b>115,954,611</b>	<b>661,873,930</b>
Finance costs		(13,550,758)	(8,188,298)	(3,205,372)	(2,382,051)
<b>Profit before taxation</b>		<b>586,415,270</b>	<b>2,388,370,851</b>	<b>112,749,239</b>	<b>659,491,879</b>
Taxation		(119,764,560)	(482,294,631)	(5,186,239)	(163,314,967)
<b>Profit after taxation</b>		<b>466,650,710</b>	<b>1,906,076,220</b>	<b>107,563,000</b>	<b>496,176,912</b>
Earnings per share - basic and diluted		<b>15.46</b>	<b>63.14</b>	<b>3.56</b>	<b>16.44</b>

The annexed notes from 1 to 16 form an integral part of this condensed interim unconsolidated financial information.

\_\_\_\_\_  
 Chief Executive Officer

\_\_\_\_\_  
 Director

**CONDENSED INTERIM UNCONSOLIDATED STATEMENT OF  
 COMPREHENSIVE INCOME (UN-AUDITED)  
 FOR THE NINE MONTHS PERIOD ENDED 31 MARCH 2017**

	Nine months period ended		Three months period ended	
	31 March 2017	31 March 2016	31 March 2017	31 March 2016
	-----Rupees-----			
<b>Profit after taxation</b>	<b>466,650,710</b>	<b>1,906,076,220</b>	<b>107,563,000</b>	<b>496,176,912</b>
Other comprehensive income for the period	-	-	-	-
<b>Total comprehensive income for the period</b>	<b><u>466,650,710</u></b>	<b><u>1,906,076,220</u></b>	<b><u>107,563,000</u></b>	<b><u>496,176,912</u></b>

The annexed notes from 1 to 16 form an integral part of this condensed interim unconsolidated financial information.

\_\_\_\_\_  
 Chief Executive Officer

\_\_\_\_\_  
 Director

**CONDENSED INTERIM UNCONSOLIDATED STATEMENT  
OF CHANGES IN EQUITY (UN-AUDITED)  
FOR THE NINE MONTHS PERIOD ENDED 31 MARCH 2017**

	Share capital	Capital reserve	Accumulated profit	Total
	Rupees			
<b>Balance as at 01 July 2015</b>	301,868,410	321,843	2,401,056,940	2,703,247,193
Total comprehensive income for the period	-	-	1,906,076,220	1,906,076,220
Surplus transferred to accumulated profit: - on account of incremental depreciation charged during the period - net of tax	-	-	4,304,452	4,304,452
<i>Transactions with owners of the Company:</i>				
- Final dividend for the year ended 30 June 2015 at Rs. 15 per share	-	-	(452,802,614)	(452,802,614)
- Interim dividend for the year ended 30 June 2016 at Rs. 10 per share	-	-	(301,868,410)	(301,868,410)
	-	-	(754,671,024)	(754,671,024)
<b>Balance as at 31 March 2016 - un-audited</b>	<u>301,868,410</u>	<u>321,843</u>	<u>3,556,766,588</u>	<u>3,858,956,841</u>
<b>Balance as at 01 July 2016</b>	301,868,410	321,843	3,765,936,024	4,068,126,277
Total comprehensive income for the period	-	-	466,650,710	466,650,710
Surplus transferred to accumulated profit: - on account of incremental depreciation charged during the period - net of tax	-	-	19,966,500	19,966,500
<i>Transactions with owners of the Company:</i>				
- Final dividend for the year ended 30 June 2016 at Rs. 12 per share	-	-	(362,242,092)	(362,242,092)
- Interim dividend for the year ended 30 June 2017 at Rs. 3 per share	-	-	(90,560,523)	(90,560,523)
	-	-	(452,802,615)	(452,802,615)
<b>Balance as at 31 March 2017 - un-audited</b>	<u>301,868,410</u>	<u>321,843</u>	<u>3,799,750,619</u>	<u>4,101,940,872</u>

The annexed notes from 1 to 16 form an integral part of this condensed interim unconsolidated financial information.

\_\_\_\_\_  
Chief Executive Officer

\_\_\_\_\_  
Director

**CONDENSED INTERIM UNCONSOLIDATED  
CASH FLOW STATEMENT (UN-AUDITED)  
FOR THE NINE MONTHS PERIOD ENDED 31 MARCH 2017**

	31 March 2017	31 March 2016
	-----Rupees-----	
<b><u>Cash flow from operating activities</u></b>		
Profit before taxation	586,415,270	2,388,370,851
<i>Adjustments for:</i>		
Depreciation	151,881,722	99,337,962
Amortisation	1,391,515	723,418
Gain on disposal of property, plant and equipment	(10,056,951)	(7,139,224)
Finance costs	13,550,758	8,188,298
Gain on re-measurement of short term investments to fair value	(9,001,585)	(29,199,661)
Gain on sale of short term investments	(3,171,520)	(22,017,455)
Profit on term deposits	(834,747)	(8,145,534)
Share in profit of Farmacia	(12,625,015)	(16,370,015)
Worker's Profit Participation Fund	31,246,017	128,269,111
Central Research Fund	6,312,327	25,912,952
Worker's Welfare Fund	7,259,052	48,742,262
	<u>175,951,573</u>	<u>228,302,114</u>
<b>Cash generated from operations before working capital changes</b>	<b>762,366,843</b>	<b>2,616,672,965</b>
Effect on cash flow due to working capital changes <i>(Increase) / decrease in current assets:</i>		
Stores, spare parts and loose tools	(5,540,687)	(12,910,951)
Advances, deposits, prepayments and other receivables	(115,481,597)	(37,124,595)
Stock in trade	142,130,710	(375,331,368)
Trade debts - considered good	(146,435,175)	(227,224,595)
	<u>(125,326,749)</u>	<u>(652,591,509)</u>
<i>(Decrease) / increase in current liabilities:</i>		
Trade and other payables	(76,265,913)	178,796,698
	<u>560,774,181</u>	<u>2,142,878,154</u>
<b>Cash generated from operations</b>	<b>191,640,094</b>	<b>1,474,084,811</b>
Taxes paid	(171,442,689)	(472,163,525)
Worker's Profit Participation Fund paid	(19,021,668)	(62,211,241)
Worker's Welfare Fund paid	(54,163,779)	(11,864,141)
Central Research Fund paid	(28,795,204)	(11,636,394)
Long term deposits	(715,000)	(12,500)
	<u>286,635,841</u>	<u>1,584,990,353</u>
<b>Net cash generated from operating activities</b>	<b>286,635,841</b>	<b>1,584,990,353</b>
<b><u>Cash flow from investing activities</u></b>		
Acquisition of property, plant and equipment	(372,622,035)	(539,447,593)
Acquisition of intangibles	-	(3,629,217)
Proceeds from sale of property, plant and equipment	14,791,302	9,888,775
Profit on term deposits	1,522,185	8,145,534
Acquisition of short term investments - net	139,587,784	(528,659,086)
	<u>(216,720,764)</u>	<u>(1,053,701,587)</u>
<b>Net cash used in investing activities</b>	<b>(216,720,764)</b>	<b>(1,053,701,587)</b>
<b><u>Cash flow from financing activities</u></b>		
Finance cost paid	(11,344,442)	(8,196,141)
Dividend paid	(439,384,721)	(728,558,036)
	<u>(450,729,163)</u>	<u>(736,754,177)</u>
<b>Net cash used in financing activities</b>	<b>(450,729,163)</b>	<b>(736,754,177)</b>
<b>Net decrease in cash and cash equivalents</b>	<b>(380,814,086)</b>	<b>(205,465,411)</b>
<b>Cash and cash equivalents at the beginning of the period</b>	<b>249,679,779</b>	<b>453,966,229</b>
<b>Cash and cash equivalents at the end of the period</b>	<b><u>(131,134,307)</u></b>	<b><u>248,500,818</u></b>
<b>Cash and cash equivalents comprise of the following:</b>		
Cash and bank balances	99,886,414	248,500,818
Running finance	(231,020,721)	-
	<u>(131,134,307)</u>	<u>248,500,818</u>

The annexed notes from 1 to 16 form an integral part of this condensed interim unconsolidated financial information.

\_\_\_\_\_  
Chief Executive Officer

\_\_\_\_\_  
Director

**NOTES TO THE CONDENSED INTERIM UNCONSOLIDATED  
FINANCIAL INFORMATION (UN-AUDITED)  
FOR THE NINE MONTHS PERIOD ENDED 31 MARCH 2017**

**1 Reporting entity**

Ferozsons Laboratories Limited ("the Company") was incorporated as a private limited company on 28 January 1954 and was converted into a public limited company on 08 September 1960. The Company is listed on the Pakistan Stock Exchange Limited and is primarily engaged in the imports, manufacture and sale of pharmaceuticals products and medical devices. Its registered office is situated at 197-A, The Mall, Rawalpindi and the factory is located at Amangarh, Nowshera, Khyber Pakhtun Khwa.

**2 Basis of preparation**

**2.1 Basis of accounting**

**2.1.1** This condensed interim unconsolidated financial information comprises the condensed interim unconsolidated balance sheet of the Company, as at 31 March 2017 and the related condensed interim unconsolidated profit and loss account, condensed interim unconsolidated statement of comprehensive income, condensed interim unconsolidated statement of changes in equity and condensed interim unconsolidated cash flow statement together with the notes forming part thereof.

**2.1.2** This condensed interim unconsolidated financial information of the Company for the nine months period ended 31 March 2017 has been prepared in accordance with the requirements of the International Accounting Standard (IAS) 34 - Interim Financial Reporting and provisions of and directives issued under the Companies Ordinance, 1984. In case where requirements differ, the provisions of or directives issued under the Companies Ordinance, 1984 have been followed.

**2.1.3** This condensed interim unconsolidated financial information does not include all of the information required for full annual financial statements and should be read in conjunction with the annual unconsolidated financial statements for the year ended 30 June 2016.

**2.1.4** Comparative unconsolidated balance sheet numbers are extracted from the annual audited unconsolidated financial statements of the Company for the year ended 30 June 2016, whereas comparative unconsolidated profit and loss account, statement of comprehensive income, statement of changes in equity and cash flow statement are stated from unaudited condensed interim unconsolidated financial information of the Company for the nine months period ended 31 March 2016.

**2.1.5** This condensed interim unconsolidated financial information is unaudited and being submitted to the shareholders as required under Section 245 of the Companies Ordinance, 1984 and the Listing Regulations of the Pakistan Stock Exchange Limited.

**2.2 Judgements and estimates**

In preparing this interim unconsolidated financial information, management has made judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates.

The significant judgments made by the management in applying the Company's accounting policies and the key sources of estimation uncertainty were the same as those that applied to the unconsolidated financial statements as at and for the year ended 30 June 2016 except for the following:

As of 30 June 2016, the Company has revised its estimate of the remaining

useful life of building on freehold land and plant and machinery. As a result, the remaining useful life of these revalued assets have been revised from 5 years to 10 years. This change in estimate of useful life of revalued assets has been applied prospectively as required under IAS-8 'Accounting policies, changes in accounting estimates and errors'. Had the useful life estimate not been revised, the depreciation charge for the current period would have been higher by Rs. 48 million for building on free hold land and Rs. 50 million for plant and machinery.

### 2.3 Statement of consistency in accounting policies

**2.3.1** The accounting policies and the methods of computation adopted in the preparation of this condensed interim unconsolidated financial information are same as those applied in the preparation of the unconsolidated financial statements for the year ended 30 June 2016.

**2.3.2** There were certain other new standards and amendments to the approved accounting standards which became effective during the period but are considered not to be relevant or have any significant effect on the Company's operations and are, therefore, not disclosed.

In addition to the above, following standards, amendments and interpretations of approved accounting standards will be effective for accounting periods beginning on or after 01 January 2017:

Standard or interpretation	Effective date (accounting periods beginning on or after)
IAS 12 - Income Taxes	01 January 2017
IAS 7 - Statement of Cash Flows	01 January 2017
IAS 40 - Investment Property	01 January 2018
IFRS 12 - Disclosure of Interests in Other Entities	01 January 2017
IFRS 2 - Share-based Payment	01 January 2018
IAS 28 - Investments in Associates and Joint Ventures	01 January 2018
IFRIC 22 - Foreign Currency Transactions and Advance Consideration	01 January 2018

	Un-Audited 31 March 2017	Audited 30 June 2016
-----Rupees-----		
<b>3 Issued, subscribed and paid up capital</b>		
1,441,952 (30 June 2016: 1,441,952) ordinary shares of Rs. 10 each fully paid in cash	<b>14,419,520</b>	14,419,520
119,600 (30 June 2016: 119,600) ordinary shares of Rs. 10 each issued in lieu of NWF Industries Limited and Sargodha Oil and Flour Mills Limited since merged	<b>1,196,000</b>	1,196,000
28,625,289 (30 June 2016: 28,625,289) ordinary shares of Rs. 10 each issued as fully paid bonus shares	<b>286,252,890</b>	286,252,890
	<b><u>301,868,410</u></b>	<u>301,868,410</u>

KFW Factors (Private) Limited, an associated company holds 8,286,942 (30 June 2016: 8,286,942) ordinary shares of Rs. 10 each of the Company.

#### 4 Short term borrowings - secured

There is no change in short term borrowing facilities available from various banks under mark up arrangements as well as under Shariah compliant arrangements secured against current assets and short term investments already disclosed in preceding annual published financial statements of the Company for the year ended 30 June 2016.

#### 5 Contingencies and commitments

##### 5.1 Contingencies

There is no significant change in contingencies already disclosed in preceding annual published financial statement of the Company for the year ended 30 June 2016.

##### 5.2 Commitments

##### 5.2.1 Letter of credits

##### 5.2.1.1 Under Mark up arrangements

Out of the aggregate facility of Rs. 600 million (30 June 2016: Rs. 600 million) for opening letters of credit, the amount utilized at 31 March 2017 for capital expenditure was Rs. 3.09 million (30 June 2016: Rs. 183.83 million) and for other than capital expenditure was Rs. 179.09 million (30 June 2016: Rs. 163.17 million). These facilities are secured by first pari passu charge of Rs. 1,000 million over all present and future current assets and fixed assets (excluding land & building) of the company.

##### 5.2.1.2 Under Shariah compliant arrangements

The Company has facility i.e. letters of credit of Rs.75 million (30 June 2016: Rs. 75 million) available from Islamic bank, the amount utilized at 31 March 2017 for capital expenditure was Rs. 2.2 million (30 June 2016: Rs. Nil) and for other than capital expenditure was Rs. 12.53 million (30 June 2016: Rs. 20.60 million). This facility is secured by first pari passu charge over current assets of the company. Lien is also marked over import documents.

	Un-Audited 31 March 2017	Audited 30 June 2016
-----Rupees-----		
<b>6 Property, plant and equipment</b>		
<b>Cost</b>		
Opening balance at beginning of the period / year	2,222,856,411	1,484,860,787
Additions during the period / year	56,777,104	133,062,401
Transfers from CWIP during the period / year	431,478,540	376,286,460
Disposals during the period / year	(24,713,688)	(34,266,895)
Revaluation surplus	-	262,913,658
Closing balance at end of the period / year	<u>2,686,398,367</u>	<u>2,222,856,411</u>
<b>Accumulated depreciation</b>		
Opening balance at beginning of the period / year	185,948,373	366,853,196
Depreciation for the period / year	151,881,722	138,760,682
On disposals	(19,979,347)	(18,589,772)
Revaluation surplus	-	(301,075,733)
Closing balance at end of the period / year	<u>317,850,748</u>	<u>185,948,373</u>
<b>Operating fixed assets - net book value</b>	<u>2,368,547,619</u>	<u>2,036,908,038</u>
<b>Capital work in progress - at cost</b>	<u>232,448,756</u>	<u>348,082,370</u>
	<u>2,600,996,375</u>	<u>2,384,990,408</u>

		Un-Audited 31 March 2017	Audited 30 June 2016
	Note	-----Rupees-----	
<b>7</b>	<b>Long term investments</b>		
	<b><u>Related parties - at cost:</u></b>		
	Farmacia (partnership firm)	7.1 <b>123,935,189</b>	111,310,174
	BF Biosciences Limited	7.2 <b>151,999,960</b>	151,999,960
		<b><u>275,935,149</u></b>	<b><u>263,310,134</u></b>

7.1 This represents the Company's 98% share in "Farmacia", a subsidiary partnership duly registered under the Partnership Act, 1932 and engaged in operating retail pharmacy. Share of profit, if any, for the period / year not withdrawn is reinvested in capital account of partnership.

7.2 This represents investment made in 15,199,996 ordinary shares of Rs. 10 each, in BF Biosciences Limited. BF Biosciences Limited has been set up for establishing a Biotech Pharmaceutical Plant to manufacture mainly Cancer and Hepatitis related medicines. The Company holds 80% of equity of the subsidiary and the remaining 20% is held by Gurpo Empresarial Bagó S.A, Argentina.

**8 Short term investments**

**Loans and receivables**

Term deposits with banks - local currency 8.1 - 335,000,000

**Investments at fair value through profit or loss - listed securities**

Held for trading	8.2	<b>207,585,321</b>	-
		<b><u>207,585,321</u></b>	<b><u>335,000,000</u></b>

8.1 The local currency short-term deposit had a maximum maturity period of 30 days, carrying profit 5.35% per annum redeemed during current period (30 June 2016: Rs. 335 million).  
The local currency short-term deposit maintained under mark up arrangements.

8.2 Following investments are classified as:

No. of units		Mutual Funds	Fair Value	
Un-audited 31 March 2017	Audited 30 June 2016		Un-audited 31 March 2017	Audited 30 June 2016
			----- Rupees -----	
<b>1,950,379</b>	-	HBL Money Market Fund	<b>207,585,321</b>	-

Changes in fair values of financial assets at fair value through profit or loss are recorded in profit and loss account. Realized gain of Rs. 3.17 million (31 March 2016: Rs. 22.02 million) has been recorded in the current period in "other income". These investments comprise of mutual funds (money market / income fund).

**8.3** Realized gain on redemption of short term investments is earned under mark up arrangements.

## 9 Cash and bank balances

**9.1** These include current account of Rs. 0.67 million (30 June 2016: Rs. 0.67 million) maintained under Shariah compliant arrangements.

**9.2** These include deposit accounts of Rs. 16.60 million (30 June 2016: Rs. 9.8 million) under mark up arrangements, which carry interest rates ranging from 3.7% - 5.35% (30 June 2016: 3.9% - 4.9%) per annum.

These also include deposit account of Rs. 2.98 million (30 June 2016: Rs. 4.6 million) under Shariah compliant arrangements, which carries profit rate ranging from 2.40% - 2.85% (30 June 2016: 2.50% - 2.85%) per annum.

	Un-audited		Un-audited	
	Nine months period ended		Three months period ended	
	31 March 2017	31 March 2016	31 March 2017	31 March 2016
	Note ----- Rupees -----			
<b>10 Revenue - net</b>				
<b>Gross sales:</b>				
Local	3,284,781,955	8,671,334,794	936,353,529	2,706,338,090
Export	139,935,535	152,930,975	26,172,029	24,250,201
	<u>3,424,717,490</u>	<u>8,824,265,769</u>	<u>962,525,558</u>	<u>2,730,588,291</u>
<b>Less:</b>				
Sales returns	(89,119,916)	(217,094,922)	(39,328,168)	(100,545,410)
Discounts and commission	(148,510,170)	(135,553,415)	(53,273,942)	(21,405,093)
Sales tax	(11,997,716)	(541,722)	(3,680,156)	(60,697)
	<u>(249,627,802)</u>	<u>(353,190,059)</u>	<u>(96,282,266)</u>	<u>(122,011,200)</u>
	<u>3,175,089,688</u>	<u>8,471,075,710</u>	<u>866,243,292</u>	<u>2,608,577,091</u>
<b>11 Cost of sales</b>				
Raw and packing materials consumed <i>11.1</i>	547,790,274	513,226,050	189,105,164	182,012,554
Other manufacturing expenses	328,019,301	260,078,387	115,719,558	90,579,853
	<u>875,809,575</u>	<u>773,304,437</u>	<u>304,824,722</u>	<u>272,592,407</u>
Opening	24,195,375	31,321,035	38,502,875	33,549,840
Closing	(40,880,120)	(37,884,973)	(40,880,120)	(37,884,973)
	<u>(16,684,745)</u>	<u>(6,563,938)</u>	<u>(2,377,245)</u>	<u>(4,335,133)</u>
<b>Cost of goods manufactured</b>	<u>859,124,830</u>	<u>766,740,499</u>	<u>302,447,477</u>	<u>268,257,274</u>
<b>Finished stock:</b>				
Opening	1,526,340,345	890,680,428	1,260,881,619	1,284,465,783
Purchases made during the period	589,453,840	4,620,865,992	173,742,116	1,257,260,692
Closing	(1,253,096,459)	(1,230,148,780)	(1,253,096,459)	(1,230,148,780)
	<u>862,697,726</u>	<u>4,281,397,640</u>	<u>181,527,276</u>	<u>1,311,577,695</u>
	<u>1,721,822,556</u>	<u>5,048,138,139</u>	<u>483,974,753</u>	<u>1,579,834,969</u>
<b>11.1 Raw and packing materials consumed</b>				
Opening	301,363,782	279,911,865	335,223,246	254,881,398
Purchases made during the period	603,892,810	519,958,053	211,348,236	213,775,024
	<u>905,256,592</u>	<u>799,869,918</u>	<u>546,571,482</u>	<u>468,656,422</u>
Closing	(357,466,318)	(286,643,868)	(357,466,318)	(286,643,868)
	<u>547,790,274</u>	<u>513,226,050</u>	<u>189,105,164</u>	<u>182,012,554</u>

- 12** The Finance Act, 2015 introduced a new tax under Section 5A of the Income Tax Ordinance, 2001 on every public company other than a scheduled bank or modaraba, that derives profits for tax year and does not distribute cash dividend within six months of the end of said tax year or distribute dividends to such an extent that its reserves, after such distribution, are in excess of 100% of its paid up capital. However, this tax on undistributed reserves is not applicable to a public company which distributes profit equal to either 40 percent of its after tax profits or 50% of its paid up capital, whichever is less, within six months of the end of the tax year.

The Board of Directors of the Company intends to distribute sufficient cash dividend for the year ended 30 June 2017. Accordingly, no provision for tax on undistributed reserves has been recognized in this condensed interim unconsolidated financial information for the period ended 31 March 2017.

**13 Transactions with related parties**

The Company's related parties include subsidiaries, associated company, entities over which directors are able to exercise influence, staff retirement fund, directors and key management personnel. Balances with the related parties are shown in respective notes in the condensed interim unconsolidated financial information. Transactions with related parties during the period are as follows:

	<b>Un-audited</b>	
	<b>Nine months period ended</b>	
	<b>31 March 2017</b>	<b>31 March 2016</b>
	----- Rupees -----	
<b><i>Farmacia - 98% owned subsidiary partnership firm</i></b>		
Sale of medicines	<b>18,608,104</b>	1,466,838
Payment received against sale of medicine	<b>18,608,104</b>	1,606,341
Share of profit reinvested	<b>12,625,015</b>	16,370,015
Rental expenses	<b>2,471,335</b>	2,246,667
<b><i>BF Biosciences Limited - 80% owned subsidiary company</i></b>		
Sale of finished goods	<b>64,340,526</b>	90,524,074
Payment received against sale of finished goods	<b>64,340,526</b>	91,312,182
Purchase of medicine	<b>1,670,936</b>	31,182,332
Payment made against purchase of medicine	<b>1,670,936</b>	31,693,597
Marketing fee / (Income)	<b>6,176,724</b>	(1,578,172)
Lease rental (income)	-	(150,000)
Expenses incurred / (reimbursed)	<b>15,541,057</b>	7,674,326
(Payment made) / received	<b>(21,717,781)</b>	(8,546,665)
<b><i>Khan &amp; Piracha - associated</i></b>		
Professional services charges	-	9,000
<b><i>Other related parties</i></b>		
Contribution towards employees' provident fund	<b>19,439,678</b>	17,235,090
Remuneration including benefits and perquisites of key management personnel	<b>103,265,328</b>	82,465,258
Payment into Workers' Profit Participation Fund	<b>19,021,668</b>	62,211,241
Dividend to KFW Factors (Private) Limited	<b>124,304,130</b>	207,304,130
Dividend to directors	<b>44,193,540</b>	87,484,910

**14 Financial risk management and financial instruments - fair value**

- 14.1 The Company's financial risk management objective and policies are consistent with that disclosed in the annual unconsolidated financial statements of the Company for the year ended 30 June 2016.

14.2 The following table shows the carrying amounts and fair values of financial assets and financial liabilities, including their levels in the fair value hierarchy. It does not include fair value information for financial assets and financial liabilities not measured at fair value if the carrying amount is a reasonable approximation of fair value.

20

	Carrying Amount		Fair Value				
	Fair Value through Income Statement	Loans and receivables	Other financial liabilities	Total	Level 1	Level 2	Level 3
----- Rupees -----							
<b>31 March 2017 - (Un-audited)</b>							
<b>Financial assets measured at fair value:</b>							
Short term investments	207,585,321	-	-	207,585,321	207,585,321	-	-
<b>Financial assets not measured at fair value:</b>							
Long term deposits	-	7,066,325	-	7,066,325	-	-	-
Trade debts - considered good	-	534,021,648	-	534,021,648	-	-	-
Loans and advances - considered good	-	1,221,344	-	1,221,344	-	-	-
Short term deposits	-	109,511,624	-	109,511,624	-	-	-
Other receivables	-	110,240	-	110,240	-	-	-
Short term investments	-	-	-	-	-	-	-
Bank balances	86,390,517	-	-	86,390,517	-	-	-
	<b>86,390,517</b>	<b>651,931,181</b>	-	<b>738,321,698</b>	-	-	-
<b>Financial liabilities measured at fair value:</b>							
Trade and other payables	-	-	409,731,982	409,731,982	-	-	-
Short term borrowings - secured	-	-	231,020,721	231,020,721	-	-	-
Accrued mark-up	-	-	2,239,083	2,239,083	-	-	-
	-	-	<b>642,991,786</b>	<b>642,991,786</b>	-	-	-
<b>30 June 2016 - (Audited)</b>							
<b>Financial assets measured at fair value:</b>							
Long term deposits	-	6,351,325	-	6,351,325	-	-	-
Trade debts - considered good	-	387,586,473	-	387,586,473	-	-	-
Loans and advances - considered good	-	972,285	-	972,285	-	-	-
Short term deposits	-	91,162,023	-	91,162,023	-	-	-
Other receivables	-	4,894,747	-	4,894,747	-	-	-
Short term investments	246,571,589	-	-	246,571,589	-	-	-
Bank balances	<b>246,571,589</b>	<b>825,966,833</b>	-	<b>1,072,538,422</b>	-	-	-
<b>Financial liabilities measured at fair value:</b>							
Trade and other payables	-	-	486,717,750	486,717,750	-	-	-
Short term borrowings - secured	-	-	32,767	32,767	-	-	-
Accrued mark-up	-	-	<b>486,750,517</b>	<b>486,750,517</b>	-	-	-

**15 Date of authorization for issue**

The Board of Directors of the Company in its meeting held on 27 April 2017 has authorized to issue these condensed interim unconsolidated financial statements.


**16 General**

**16.1** Corresponding figures have been re-arranged, wherever necessary, for the purpose of comparison and better presentation as per reporting framework.

**16.2** Figures have been rounded off to the nearest rupee.

\_\_\_\_\_  
Chief Executive Officer

\_\_\_\_\_  
Director





---

***Condensed Interim  
Consolidated Financial  
Information for the  
Nine Months Period  
Ended 31 March 2017***

---



**CONDENSED INTERIM CONSOLIDATED BALANCE SHEET  
 AS AT 31 MARCH 2017**

		Un-Audited 31 March 2017	Audited 30 June 2016
	Note	-----Rupees-----	
<b>EQUITY AND LIABILITIES</b>			
<b><u>Share capital and reserves</u></b>			
Authorized share capital 50,000,000 (30 June 2016: 50,000,000) ordinary shares of Rs. 10 each		<u>500,000,000</u>	<u>500,000,000</u>
Issued, subscribed and paid up capital	4	<b>301,868,410</b>	301,868,410
Capital reserve		<b>321,843</b>	321,843
Accumulated profit		<u>4,340,743,337</u>	4,279,679,051
<b>Equity attributable to owners of the Company</b>		<b>4,642,933,590</b>	4,581,869,304
<b>Non-controlling interests</b>		<u>175,487,221</u>	168,681,094
		<b>4,818,420,811</b>	4,750,550,398
<b>Surplus on revaluation of property, plant and equipment - net of tax</b>		<b>987,660,377</b>	1,022,739,340
<b><u>Non current liabilities</u></b>			
Deferred taxation		<b>270,564,989</b>	268,664,070
<b><u>Current liabilities</u></b>			
Trade and other payables		<b>647,796,265</b>	778,287,566
Short term borrowings - secured	5	<b>231,020,721</b>	42,851,551
Accrued mark-up		<b>2,239,083</b>	138,692
		<u>881,056,069</u>	821,277,809
		<u><b>6,957,702,246</b></u>	<u>6,863,231,617</u>
<b>Contingencies and commitments</b>	6		

The annexed notes from 1 to 16 form an integral part of these condensed interim consolidated financial information.

\_\_\_\_\_  
 Chief Executive Officer

	<b>Un-Audited 31 March 2017</b>	<b>Audited 30 June 2016</b>
<b>ASSETS</b>	<b>Note</b>	<b>-----Rupees-----</b>
<b><u>Non-current assets</u></b>		
Property, plant and equipment	7	3,009,074,944
Intangibles		5,539,396
Long term deposits		10,338,325
		<u>3,161,725,833</u>
<b><u>Current assets</u></b>		
Stores, spare parts and loose tools		44,734,010
Stock in trade		2,071,316,936
Trade debts - considered good		447,354,701
Loans and advances - considered good		43,691,073
Deposits and prepayments		116,441,665
Other receivables		7,637,820
Short term investments	8	667,166,585
Income tax - net		55,178,359
Cash and bank balances	9	384,757,803
		<u>3,795,976,413</u>
		<u>3,838,278,952</u>
		<u><u>6,957,702,246</u></u>
		<u><u>6,863,231,617</u></u>

\_\_\_\_\_  
Director

**CONDENSED INTERIM CONSOLIDATED  
 PROFIT AND LOSS ACCOUNT (UN-AUDITED)  
 FOR THE NINE MONTHS PERIOD ENDED 31 MARCH 2017**

	Note	Nine months period ended		Three months period ended	
		31 March 2017	31 March 2016	31 March 2017	31 March 2016
		<b>Rupees</b>			
Revenue - net	10	3,710,299,172	9,337,846,490	1,043,690,465	2,869,966,831
Cost of sales	11	(2,123,282,878)	(5,530,639,598)	(624,305,547)	(1,754,940,561)
<b>Gross profit</b>		<b>1,587,016,294</b>	<b>3,807,206,892</b>	<b>419,384,918</b>	<b>1,115,026,270</b>
Administrative expenses		(241,568,607)	(207,520,713)	(83,440,035)	(67,744,668)
Selling and distribution expenses		(722,420,417)	(853,872,877)	(229,076,439)	(302,119,250)
Other expenses		(50,891,715)	(256,291,430)	(5,865,698)	(92,883,037)
Other income		51,722,931	101,864,914	22,070,331	38,014,479
<b>Profit from operations</b>		<b>623,858,486</b>	<b>2,591,386,786</b>	<b>123,073,077</b>	<b>690,293,794</b>
Finance costs		(14,819,284)	(9,145,282)	(3,566,485)	(2,687,794)
<b>Profit before taxation</b>		<b>609,039,202</b>	<b>2,582,241,504</b>	<b>119,506,592</b>	<b>687,606,000</b>
Taxation		(123,445,136)	(536,675,833)	(8,466,070)	(167,597,681)
<b>Profit after taxation</b>		<b>485,594,066</b>	<b>2,045,565,671</b>	<b>111,040,522</b>	<b>520,008,319</b>
Attributable to:					
Owners of the Company		481,810,432	2,016,404,116	110,114,404	515,125,620
Non-controlling interests		3,783,634	29,161,555	926,118	4,882,699
<b>Profit after taxation</b>		<b>485,594,066</b>	<b>2,045,565,671</b>	<b>111,040,522</b>	<b>520,008,319</b>
Earnings per share - basic and diluted		15.96	66.80	3.65	17.06

The annexed notes from 1 to 16 form an integral part of these condensed interim consolidated financial information.

\_\_\_\_\_  
 Chief Executive Officer

\_\_\_\_\_  
 Director

**CONDENSED INTERIM CONSOLIDATED STATEMENT OF  
 COMPREHENSIVE INCOME (UN-AUDITED)  
 FOR THE NINE MONTHS PERIOD ENDED 31 MARCH 2017**

	Nine months period ended		Three months period ended	
	31 March 2017	31 March 2016	31 March 2017	31 March 2016
	----- Rupees -----			
<b>Profit after taxation</b>	<b>485,594,066</b>	2,045,565,671	<b>111,040,522</b>	520,008,319
Other comprehensive income for the period	-	-	-	-
<b>Total comprehensive income for the period</b>	<b>485,594,066</b>	2,045,565,671	<b>111,040,522</b>	520,008,319
<b>Attributable to:</b>				
Owners of the Company	<b>481,810,432</b>	2,016,404,116	<b>110,114,404</b>	515,125,620
Non-controlling interests	<b>3,783,634</b>	29,161,555	<b>926,118</b>	4,882,699
	<b>485,594,066</b>	2,045,565,671	<b>111,040,522</b>	520,008,319

The annexed notes from 1 to 16 form an integral part of these condensed interim consolidated financial information.

\_\_\_\_\_  
 Chief Executive Officer

\_\_\_\_\_  
 Director

**CONDENSED INTERIM CONSOLIDATED STATEMENT  
OF CHANGES IN EQUITY (UN-AUDITED)  
FOR THE NINE MONTHS PERIOD ENDED 31 MARCH 2017**

	Attributable to Owners of the Company			Non-controlling interests	Total	
	Share capital	Capital reserve	Accumulated profit			
	----- Rupees -----					
Balance as at 01 July 2015	301,868,410	321,843	2,811,333,056	3,113,523,309	138,654,363	3,252,177,672
Total comprehensive income for the period	-	-	2,016,404,116	2,016,404,116	29,161,555	2,045,565,671
Surplus transferred to accumulated profit: -on account of incremental depreciation charged during the period - net of tax	-	-	7,239,938	7,239,938	733,872	7,973,810
<b>Transactions with owners of the Company:</b>						
-Final dividend for the year ended 30 June 2015 at Rs. 15 per share			(452,802,614)	(452,802,614)	-	(452,802,614)
-Interim dividend for the year ended 30 June 2016 at Rs. 10 per share			(301,868,410)	(301,868,410)	-	(301,868,410)
			(754,671,024)	(754,671,024)	-	(754,671,024)
Balance as at 31 March 2016 - unaudited	301,868,410	321,843	4,080,306,086	4,382,496,339	168,549,790	4,551,046,129
Balance as at 01 July 2016	301,868,410	321,843	4,279,679,051	4,581,869,304	168,681,094	4,750,550,398
Total comprehensive income for the period	-	-	481,810,432	481,810,432	3,783,634	485,594,066
Surplus transferred to accumulated profit: -on account of incremental depreciation charged during the period - net of tax	-	-	32,056,469	32,056,469	3,022,493	35,078,962
<b>Transactions with owners of the Company:</b>						
-Final dividend for the year ended 30 June 2016 at Rs. 12 per share	-	-	(362,242,092)	(362,242,092)	-	(362,242,092)
-Interim dividend for the year ended 30 June 2017 at Rs. 3 per share	-	-	(90,560,523)	(90,560,523)	-	(90,560,523)
	-	-	(452,802,615)	(452,802,615)	-	(452,802,615)
Balance as at 31 March 2017 - unaudited	301,868,410	321,843	4,340,743,337	4,642,933,590	175,487,221	4,818,420,811

The annexed notes from 1 to 16 form an integral part of these condensed interim consolidated financial information.

\_\_\_\_\_  
Chief Executive Officer

\_\_\_\_\_  
Director

**CONDENSED INTERIM CONSOLIDATED  
CASH FLOW STATEMENT (UN-AUDITED)  
FOR THE NINE MONTHS PERIOD ENDED 31 MARCH 2017**

	31 March 2017	31 March 2016
	-----Rupees-----	
<b><i>Cash flow from operating activities</i></b>		
Profit before taxation	609,039,202	2,582,241,504
<i>Adjustments for:</i>		
Depreciation	239,723,881	168,818,055
Amortisation	1,775,185	1,132,513
Gain on disposal of property, plant and equipment	(12,425,883)	(8,977,122)
Finance costs	14,819,284	9,145,282
Provision for doubtful debts	6,000	-
Un-realised gain on re-measurement of short term investments to fair value	(30,810,589)	(44,420,425)
Gain on sale of short term investments	(3,971,927)	(22,605,059)
Profit on term deposits	(834,747)	(8,145,534)
Workers' Profit Participation Fund	33,669,021	139,374,121
Workers' Welfare Fund	8,337,176	52,962,166
Central Research Fund	6,801,823	28,156,388
	<u>257,089,224</u>	<u>315,440,385</u>
<b>Cash generated from operations before working capital changes</b>	<b>866,128,426</b>	<b>2,897,681,889</b>
<b><i>Effect on cash flow due to working capital changes</i></b>		
<b><i>Decrease / (increase) in current assets</i></b>		
Stores, spare parts and loose tools	(7,328,025)	(14,297,076)
Loans, advances, deposits and prepayments	(111,078,285)	(42,065,588)
Stock in trade	87,700,871	(453,173,668)
Trade debts - considered good	(165,966,889)	(250,801,078)
	<u>(196,672,328)</u>	<u>(760,337,410)</u>
<b><i>(Decrease) / increase in current liabilities</i></b>		
Trade and other payables	(73,710,034)	227,769,262
	<u>(73,710,034)</u>	<u>227,769,262</u>
<b>Cash generated from operations</b>	<b>595,746,064</b>	<b>2,365,113,741</b>
Taxes paid	(195,052,053)	(539,757,214)
Workers' Profit Participation Fund paid	(28,875,639)	(77,680,616)
Workers' Welfare Fund paid	(58,846,725)	(17,669,077)
Central Research Fund paid	(31,284,809)	(14,722,485)
Long term deposits	(715,000)	(12,500)
	<u>(280,971,838)</u>	<u>(652,848,932)</u>
<b>Net cash generated from operating activities</b>	<b>280,971,838</b>	<b>1,715,271,849</b>
<b><i>Cash flow from investing activities</i></b>		
Acquisition of property, plant and equipment	(383,347,827)	(563,110,301)
Acquisition of intangibles	-	(5,164,117)
Proceeds from sale of property, plant and equipment	18,216,467	13,086,342
Profit on term deposits	834,747	8,145,534
Acquisition of short term investments - net	174,587,783	(892,115,100)
	<u>(189,708,830)</u>	<u>(1,439,157,642)</u>
<b>Net cash used in investing activities</b>	<b>(189,708,830)</b>	<b>(1,439,157,642)</b>
<b><i>Cash flow from financing activities</i></b>		
Finance cost paid	(12,718,893)	(9,153,125)
Dividend paid	(439,384,721)	(728,558,036)
	<u>(452,103,614)</u>	<u>(737,711,161)</u>
<b>Net cash used in financing activities</b>	<b>(452,103,614)</b>	<b>(737,711,161)</b>
<b>Net decrease in cash and cash equivalents</b>	<b>(360,840,606)</b>	<b>(461,596,954)</b>
<b>Cash and cash equivalents at the beginning of the period</b>	<b>341,906,252</b>	<b>780,166,802</b>
<b>Cash and cash equivalents at the end of the period</b>	<b>(18,934,354)</b>	<b>318,569,848</b>
<b>Cash and cash equivalents comprise of the following:</b>		
Cash and bank balances	212,086,367	329,868,143
Running finance	(231,020,721)	(11,298,295)
	<u>(18,934,354)</u>	<u>318,569,848</u>

The annexed notes from 1 to 16 form an integral part of these condensed interim consolidated financial information.

\_\_\_\_\_  
Chief Executive Officer

\_\_\_\_\_  
Director

## **NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL INFORMATION (UN-AUDITED) FOR THE NINE MONTHS PERIOD ENDED 31 MARCH 2017**

### **1 The Group and its operation**

Ferozsons Laboratories Limited (“the Holding Company”) was incorporated as a private limited company on 28 January 1954 and was converted into a public limited company on 08 September 1960. The Holding Company is listed on the Pakistan Stock Exchange Limited and is primarily engaged in the imports, manufacture and sale of pharmaceuticals products and medical devices. Its registered office is situated at 197-A, The Mall, Rawalpindi and the factory is located at Amangarh, Nowshera, Khyber Pakhtoon Khwa.

BF Biosciences Limited is an 80% owned subsidiary of the Holding Company and was incorporated as an unquoted public limited company under the Companies Ordinance, 1984 on 24 February 2006. BF Biosciences Limited has been set up for establishing a biotech pharmaceutical plant to manufacture cancer and hepatitis related medicines.

The Holding Company has 98% holding in Farmacia. Farmacia is a partnership duly registered under Partnership Act, 1932. Farmacia is engaged in the retail trading of pharmaceutical products.

### **2 Basis of consolidation**

These consolidated financial information includes the financial statements of Ferozsons Laboratories Limited and its subsidiaries – BF Biosciences Limited and Farmacia (“hereinafter referred as the Group”).

Subsidiaries are those entities, including an unincorporated entities such as a partnership that are controlled by another entity (known as the parent). The financial statements of the subsidiaries are included in the consolidated financial information from the date the control commences, until the date when that control ceases. The financial statements of the subsidiaries have been consolidated on line by line basis. Details of the subsidiaries are given in note 1.

All material inter-organization balances, transactions and resulting unrealized profits / losses have been eliminated.

### **3 Basis of preparation**

#### **3.1 Basis of accounting**

**3.1.1** This condensed interim consolidated financial information comprises the condensed interim consolidated balance sheet of the Holding Company, as at 31 March 2017 and the related condensed interim consolidated profit and loss account, condensed interim consolidated statement of comprehensive income, condensed interim consolidated statement of changes in equity and condensed interim consolidated cash flow statement together with the notes forming part thereof.

**3.1.2** This condensed interim consolidated financial information is presented in accordance with the requirements of International Accounting Standard 34 “Interim Financial Reporting” and provisions of and directives issued under the Companies Ordinance, 1984. In case where requirements differ, the provisions of or directives issued under the Companies Ordinance, 1984 have been followed.

**3.1.3** This condensed interim consolidated financial information do not include all of the information required for annual financial statements, and should be read in conjunction with the financial statements of the Holding Company as at and for the year ended 30 June 2016.

**3.1.4** Comparative figures of the balance sheet are extracted from the annual financial statements for the year ended 30 June 2016, whereas comparative profit and loss account, statement of comprehensive income, statement of changes in equity and statement of cash flows are stated from un-audited condensed interim consolidated financial information for the nine months period ended on 31 March 16.

**3.1.5** The condensed interim consolidated financial information is un-audited and is being submitted to the shareholders as required under Section 245 of the Companies Ordinance, 1984 and the Listing Regulations of the Pakistan Stock Exchange Limited.

### **3.2 Judgements and estimates**

In preparing this interim consolidated financial information, management has made judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates.

The significant judgments made by the management in applying the Group's accounting policies and the key sources of estimation uncertainty were the same as those that applied to the consolidated financial statements as at and for the year ended 30 June 2016 except for the following:

As of 30 June 2016, the Holding Company has revised its estimate of the remaining useful life of building on freehold land and plant and machinery. As a result, the remaining useful life of these revalued assets have been revised from 5 years to 10 years. This change in estimate of useful life of revalued assets has been applied prospectively as required under IAS-8 'Accounting policies, changes in accounting estimates and errors'. Had the useful life estimate not been revised, the depreciation charge for the current period would have been higher by Rs. 48 million for building on free hold land and Rs. 49.65 million for plant and machinery.

### **3.3 Statement of consistency in accounting policies**

**3.2.1** The accounting policies and the methods of computation adopted in the preparation of this condensed interim consolidated financial information are same as those applied in the preparation of the consolidated financial statements for the year ended 30 June 2016.

**3.2.2** There were certain other new standards and amendments to the approved accounting standards which became effective during the period but are considered not to be relevant or have any significant effect on the Group's operations and are, therefore, not disclosed.

In addition to the above, following standards, amendments and interpretations of approved accounting standards will be effective for accounting periods beginning on or after 01 January 2017:

<b>Standard or interpretation</b>	<b>Effective date (accounting periods beginning on or after)</b>
IAS 12 - Income Taxes	01 January 2017
IAS 7 - Statement of Cash Flows	01 January 2017
IAS 40 - Investment Property	01 January 2018
IFRS 12 - Disclosure of Interests in Other Entities	01 January 2017
IFRS 2 - Share-based Payment	01 January 2018
IAS 28 - Investments in Associates and Joint Ventures	01 January 2018
IFRIC 22 - Foreign Currency Transactions and Advance Consideration	01 January 2018

	<b>Un-Audited 31 March 2017</b>	<b>Audited 30 June 2016</b>
	-----Rupees-----	
<b>4 Issued, subscribed and paid up capital</b>		
1,441,952 (30 June 2016: 1,441,952) ordinary shares of Rs. 10 each fully paid in cash	<b>14,419,520</b>	14,419,520
119,600 (30 June 2016: 119,600) ordinary shares of Rs. 10 each issued in lieu of NWF Industries Limited and Sargodha Oil and Flour Mills Limited since merged	<b>1,196,000</b>	1,196,000
28,625,289 (30 June 2016: 28,625,289) ordinary shares of Rs. 10 each issued as fully paid bonus shares	<u><b>286,252,890</b></u>	<u>286,252,890</u>
	<u><b>301,868,410</b></u>	<u>301,868,410</u>

**5 Short term borrowings - secured**

There is no change in short term borrowing facilities available from various banks under mark up arrangements as well as under Shariah compliant arrangements secured against current assets and short term investments already disclosed in preceding annual published consolidated financial statements of the Holding Company for the year ended 30 June 2016.

**6 Contingencies and commitments**

**6.1 Contingencies:**

There is no significant change in contingencies already disclosed in preceding annual published financial statement of the Holding Company for the year ended 30 June 2016.

**6.2 Commitments**

**6.2.1 Letter of credits**

**6.2.1.1 Under Mark up arrangements**

Out of the aggregate facility of Rs. 850 million (30 June 2016: Rs. 850 million) for opening letters of credit, the amount utilized by the Group at 31 March 2017 for capital expenditure was Rs. 3.09 million (30 June 2016: Rs. 183.83 million) and for other than capital expenditure was Rs. 192.09 million (30 June 2016: Rs. 217.17 million).

**6.2.1.2 Under Shariah compliant arrangements**

The Holding Company has facility i.e letters of credit of Rs.75 million (30 June 2016: Rs. 75 million) availed from Islamic bank, the amount utilized at 31 March 2017 for capital expenditure was Rs. 2.2 million (30 June 2016: Rs. Nil) and for other than capital expenditure was Rs. 12.53 million (30 June 2016: Rs. 20.60 million). This facility is secured by first pari passu charge over current assets of the Holding Company. Lien is also marked over import documents.

	Un-Audited 31 March 2017	Audited 30 June 2016
<b>7</b>		
<b>Property, plant and equipment</b>		
<b>Cost</b>		
Opening balance	2,907,402,205	2,416,957,048
Additions during the period / year	58,456,542	144,141,959
Transfer / adjustment during the period / year	443,212,007	401,392,416
Disposals during the period / year	(30,501,139)	(30,491,276)
Revaluation surplus	-	(24,597,942)
Closing balance	<b>3,378,569,615</b>	2,907,402,205
<b>Accumulated depreciation</b>		
Opening balance	252,545,028	846,991,392
Depreciation for the period / year	239,723,881	233,406,272
Relating to disposals	(24,710,555)	(24,792,574)
Revaluation surplus	-	(803,060,062)
Closing balance	<b>467,558,354</b>	252,545,028
<b>Operating assets-net book value</b>	<b>2,911,011,261</b>	2,654,857,177
<b>Capital work in progress</b>	<b>235,897,045</b>	354,217,767
<b>Net book value</b>	<b>3,146,908,306</b>	3,009,074,944

**8 Short term investments**
**Loans and receivables**

Term deposits with banks - local currency 8.1 - 335,000,000

**Investments at fair value through profit or loss - listed securities**

Held for trading 8.2 **527,361,318** 332,166,585

**527,361,318** **667,166,585**

**8.1** The local currency short-term deposit had a maximum maturity period of 30 days, carrying profit 5.35 % per annum redeemed during current period (30 June 2016: Rs. 335 million).  
The local currency short-term deposit maintained under mark up arrangements.

**8.2** Following investments are classified as:

No. of units		Mutual Funds	Fair value	
Un-audited 31 March 2017	Audited 30 June 2016		Un-audited 31 March 2017	Audited 30 June 2016
			----- Rupees -----	
4,343,375	5,126,903	MCB Pakistan Cash Management Fund	231,404,178	257,366,938
189,850	189,850	MCB Pakistan Stock Market Fund	21,864,001	16,534,010
151,800	255,964	Faysal Money Market Fund	16,175,789	25,941,373
3,210,833	3,206,485	ABL Government Securities Fund	33,906,716	32,200,804
1,951,595	1,216	HBL Money Market Fund	207,714,722	123,460
149,120	-	Investment in Faysal MTS Fund	15,538,324	-
7,124	-	Faysal Bank Savings Growth Fund	757,587	-
			<b>527,361,318</b>	<b>332,166,585</b>

**8.3** Changes in fair values of financial assets at fair value through profit or loss are recorded in profit and loss account. Realized gain of Rs. 3.97 million (31 March 2016: Rs. 22.61 million) has been recorded in the current period in "other income". These investments comprise of mutual funds (money market / income fund).

**8.4** Realized gain on redemption of short term investments is earned under mark up arrangements.

## 9 Cash and bank balances

**9.1** These include current account of Rs. 0.67 million (30 June 2016: Rs. 0.67 million) maintained under Shariah compliant arrangements.

**9.2** These include deposit accounts of Rs. 80.86 million (30 June 2016: Rs. 89.14 million) under mark up arrangements, which carry interest rates ranging from 3.7% - 5.35% (30 June 2016: 3.82% - 6%) per annum.

These also include deposit account of Rs. 2.98 million (30 June 2016: Rs. 4.6 million ) under Shariah compliant arrangements, which carries profit rate ranging from 2.40% - 2.85% (30 June 2016: 2.50% - 2.85%) per annum.

Un-audited		Un-audited	
Nine months period ended		Three months period ended	
31 March	31 March	31 March	31 March
2017	2016	2017	2016
----- Rupees -----			

Note

## 10 Revenue - net

### Gross sales:

Local	3,890,494,940	9,634,897,846	1,127,541,354	3,001,077,173
Export	161,279,776	161,369,610	30,201,912	24,250,201
	<b>4,051,774,716</b>	<b>9,796,267,456</b>	<b>1,157,743,266</b>	<b>3,025,327,374</b>

### Less:

Sales returns	(101,851,176)	(223,792,102)	(43,635,320)	(106,355,931)
Discounts and commission	(224,898,123)	(232,792,304)	(65,775,123)	(48,477,319)
Sales tax	(14,726,245)	(1,836,560)	(4,642,358)	(527,293)
	<b>(341,475,544)</b>	<b>(458,420,966)</b>	<b>(114,052,801)</b>	<b>(155,360,543)</b>
	<b>3,710,299,172</b>	<b>9,337,846,490</b>	<b>1,043,690,465</b>	<b>2,869,966,831</b>

## 11 Cost of sales

Raw and packing materials consumed	11.1	610,696,941	740,907,283	208,050,472	232,351,668
Other manufacturing expenses		514,334,711	440,157,342	174,756,468	150,647,753
		<b>1,125,031,652</b>	<b>1,181,064,625</b>	<b>382,806,940</b>	<b>382,999,421</b>

### Work in process:

Opening	96,389,128	44,914,516	96,783,220	119,110,192
Closing	(86,336,685)	(109,378,366)	(86,336,685)	(109,378,366)
	<b>10,052,443</b>	<b>(64,463,850)</b>	<b>10,446,535</b>	<b>9,731,826</b>

### Cost of goods manufactured

	<b>1,135,084,095</b>	<b>1,116,600,775</b>	<b>393,253,475</b>	<b>392,731,247</b>
--	----------------------	----------------------	--------------------	--------------------

### Finished stock:

Opening	1,597,678,787	956,803,313	1,367,958,863	1,368,311,812
Purchases made during the period	738,235,309	4,758,187,952	210,808,522	1,294,849,944
Closing	(1,347,715,313)	(1,300,952,442)	(1,347,715,313)	(1,300,952,442)
	<b>988,198,783</b>	<b>4,414,038,823</b>	<b>231,052,072</b>	<b>1,362,209,314</b>
	<b>2,123,282,878</b>	<b>5,530,639,598</b>	<b>624,305,547</b>	<b>1,754,940,561</b>

Un-audited		Un-audited	
Nine months period ended		Three months period ended	
31 March	31 March	31 March	31 March
2017	2016	2017	2016

-----Rupees-----

**11.1 Raw and packing materials consumed**

Opening	357,353,488	365,200,196	449,478,950	322,105,187
Purchases made during the period	729,502,991	738,740,105	234,731,060	273,279,499
	<b>1,086,856,479</b>	1,103,940,301	<b>684,210,010</b>	595,384,686
Closing	(476,159,538)	(363,033,018)	(476,159,538)	(363,033,018)
	<b>610,696,941</b>	740,907,283	<b>208,050,472</b>	232,351,668

- 12** The Finance Act, 2015 introduced a new tax under Section 5A of the Income Tax Ordinance, 2001 on every public company other than a scheduled bank or modaraba, that derives profits for tax year and does not distribute cash dividend within six months of the end of said tax year or distribute dividends to such an extent that its reserves, after such distribution, are in excess of 100% of its paid up capital. However, this tax on undistributed reserves is not applicable to a public company which distributes profit equal to either 40 percent of its after tax profits or 50% of its paid up capital, whichever is less, within six months of the end of the tax year.

The Board of Directors of the Holding Company intends to distribute sufficient cash dividend for the year ended 30 June 2017. Accordingly, no provision for tax on undistributed reserves has been recognized in this condensed interim consolidated financial information for the period ended 31 March 2017.

**13 Transactions with related parties**

The related parties include associated companies, contributory provident fund, major shareholders, directors and key management personnel. Balances with the related parties are shown elsewhere in the accounts. Transactions with related parties during the period are as follows:

	Un-audited	
	Nine months period ended	
	31 March	30 June
	2017	2016

-----Rupees-----

<b>Other related parties</b>		
Contribution towards employees' provident fund	23,652,197	21,232,783
Remuneration including benefits and perquisites of key management personnel	126,314,448	96,464,052

**14 Financial risk management and financial instruments - fair value**

- 14.1** The Group's financial risk management objective and policies are consistent with that disclosed in the annual consolidated financial statements of the Holding Company for the year ended 30 June 2016.



**15 Date of authorization for issue**

The Board of Directors of the Holding Company in its meeting held on 27 April 2017 has authorized to issue these condensed interim consolidated financial statements.

**16 General**

**16.1** Corresponding figures have been re-arranged, wherever necessary, for the purpose of comparison and better presentation as per reporting framework.

**16.2** Figures have been rounded off to the nearest rupee.

\_\_\_\_\_  
Chief Executive Officer

\_\_\_\_\_  
Director

PEOPLE  
TRUST  
US

**MORE THAN SIX DECADES  
OF DEDICATED SERVICE  
TO HUMANITY IN PAKISTAN  
AND AROUND THE WORLD  
IN PHARMACEUTICALS**



**FEROZSONS**  
LABORATORIES LIMITED

Registered Office: 197-A, The Mall, Rawalpindi, 46000 (Pakistan)  
Phones: +92-51-4252155-57 Fax: +92-51-4252153  
email: [cs@ferozsons-labs.com](mailto:cs@ferozsons-labs.com) [www.ferozsons-labs.com](http://www.ferozsons-labs.com)